The Medical College of Georgia has again been designated by the National Cancer Institute as a Minority-Based Community Clinical Oncology Program.
The renewal, which comes with a five-year $2.3 million grant, provides more access to the latest cancer treatment and prevention strategies for all cancer patients, particularly minorities, says Dr. Anand Jillella, chief of the MCG section of Hematology/Oncology and principal investigator on the grant.
The real advantage of the grant is that it is minority-based, which is really relevant here because we have such a significant number of minority patients, says Dr. Kapil N. Bhalla, director of the Medical College of Georgia Cancer Center. The National Cancer Institute recognizes the need to extend studies and clinical trials to those populations and this grant enables us to help advance that initiative by supporting the work done by cancer researchers and clinicians here. This type of work is integral to the overall mission of the Cancer Center - to facilitate and inspire cancer research. It is the perfect marriage of our clinical and research components.
MCG, eligible because more than 40 percent of its newly-diagnosed patients and 40 percent of patients enrolled in clinical trials are minorities, first received the designation in 2004.
The Veterans Affairs Medical Center in Augusta, Aiken Regional Medical Center in Aiken, S.C., and Athens Regional Medical Center in Athens, Ga., are collaborators on the grant.
Dr. Daron G. Ferris, family medicine physician and director of the Gynecologic Cancer Prevention Center at MCG, and Dr. Roger A. Vega, chief of the MCG Section of Pediatric Hematology/Oncology are co-principal investigators.
This designation allows us to continue to broaden the scope of clinical trials and prevention programs by providing support for the infrastructure those initiatives require, Dr. Jillella says.
Unlike the typical grant, prog
|Contact: Jennifer Hilliard|
Medical College of Georgia